“Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s29. doi:10.25251/skin.5.supp.29.